Search Results for "biomarker" | Oncology Voice Network

Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Feb 23^rd • 8 mins read

Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Feb 22^nd • 10 mins read

J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Sep 26^th • 17 mins read

Consolación Molto MD, Thomas J. Hwang AB, Maria Borrell MD, Marta Andres MD, Ignasi Gich MD, PhD, Agustí Barnadas MD, PhD, Eitan Amir MD, PhD, Aaron S. Kesselheim MD, JD, MPH, Ariadna Tibau MD, PhD

Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

Jul 22^nd • 12 mins read

Muneera Al Hussain

Comment on: Oncology research in Saudi Arabia over a 10-year period. A synopsis

Jun 24^th • 3 mins read

Jonathan H. Cheng, Justin W. Tiulim, Sheng Zhou, Anthony El-Khoueiry and Jorge Nieva

Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials

Oct 18^th • 10 mins read

S.E. Abdullah, E. Oflazoglu, J.C. Soria, M.M. Dar

New Realities of Phase I Clinical Trials in the Era of

Oct 7^th • 5 mins read

J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Sep 26^th • 16 mins read

Guillaume Beinse, MD, Virgile Tellier, Valentin Charvet, MSc, Eric Deutsch, MD, PhD, Isabelle Borget, PharmD, PhD, Christophe Massard, MD, PhD., Antoine Hollebecque, MD, PhD, and Loic Verlingue, MD

Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2

Sep 20^th • 12 mins read

Emerson Y. Chen, MD, Alyson Haslam, PhD, Vinay Prasad, MD

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019

Mar 9^th • 4 mins read

Kirsten B Goldberg, Gideon M Blumenthal, Amy E McKee and Richard Pazdur

The FDA Oncology Center of Excellence and Precision Medicine

Nov 6^th • 3 mins read

Navigation

Results for 'biomarker'

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

Comment on: Oncology research in Saudi Arabia over a 10-year period. A synopsis

Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials

New Realities of Phase I Clinical Trials in the Era of

Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Prediction of Drug Approval After Phase I Clinical Trials in Oncology: RESOLVED2

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019

The FDA Oncology Center of Excellence and Precision Medicine

Related Topics